Continuous glucose monitoring: Current use and future directions

Current Diabetes Reports

Volumn 13, Issue 5, 2013, Pages 657-662

  Desalvo, Daniel ^a   Buckingham, Bruce ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Artificial pancreas; Closed loop system; Continuous glucose monitoring; Nocturnal hypoglycemia; Type 1 diabetes

Indexed keywords

GLUCOSE; GLUCOSE OXIDASE; HEMOGLOBIN A1C; INSULIN;

ACCURACY; ARTICLE; ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; ELECTRIC CURRENT; ELECTROCHEMICAL ANALYSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL FLUID; MONITOR; RELIABILITY; SENSOR;

BLOOD GLUCOSE SELF-MONITORING; FEASIBILITY STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPOGLYCEMIA; REPRODUCIBILITY OF RESULTS;

EID: 84884589359     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0398-4     Document Type: Article

References (48)

1. Davis EA, Keating B, Byrne GC, et al. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care. 1997;20:22-5.
2. Mastrototaro JJ. The MiniMed continuous glucose monitoring system. Diabetes Technol Ther. 2000;2 Suppl 1:S13-8.
3. Feldman B, Brazg R, Schwartz S, et al. A continuous glucose sensor based on wired enzyme technology - results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther. 2003;5:769-79.
4. Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29:44-50.
5. Hirsch IB, Abelseth J, Bode BW, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther. 2008;10:377-83.
6. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464-76.
7. • Tamborlane W, Beck R, Laffel L. Continuous glucose monitoring and type 1 Diabetes. N Engl J Med. 2009;360:1901-192. This landmark study of CGM demonstrated that almost daily use of CGM is required to achieve significant improvements in A1c levels without increasing the risk of hypoglcyemia, and adults were more consistent with CGM use compared with children and adolescents.
8. Deiss D, Bolinder J, Riveline JP, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29:2730-2.
9. O'Connell MA, Donath S, O'Neal DN, et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia. 2009;52:1250-7.
10. Chase HP, Beck RW, Xing D, et al. Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Technol Ther. 2010;12:507-15.
11. • Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311-20. This is the largest randomized trial of CGM use and demonstrated that sensor augmented pump therapy achieved significant improvements in A1c levels along with a very low incidence of severe hypoglycemic events in children, adolescents, and adults.
12. Buckingham B, Wilson DM, Lecher T, et al. Duration of nocturnal hypoglycemia prior to seizures. Diabetes Care. 2008;31:2110-2.
13. Cobry E, McFann K, Messer L, et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010;12:173-7.
14. Smith CB, Choudhary P, Pernet A, et al. Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit. Diabetes Care. 2009;32:1196-8.
15. Tsalikian E, Tamborlane W, Xing D, et al. Blunted counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes. Diabetes Care. 2009;32:1954-9.
16. Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med. 1998;338:1657-62.
17. Ly TT, Hewitt J, Davey R, et al. Improving epinephrine responses in hypoglycemia unawareness with real-time continuous glucose monitoring in adolescents with type 1 diabetes. Diabetes Care. 2011;34:50-2.
18. Mesotten D, Van den Berghe G. Clinical potential of insulin therapy in critically ill patients. Drugs. 2003;63:625-36.
19. Finfer S, Chittock DR, Su S, et al. Intensive vs conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283-97.
20. Holzinger U, Warszawska J, Kitzberger R, et al. Real-time continuous glucose monitoring in critically ill patients: a prospective randomized trial. Diabetes Care. 2010;33:467-72.
21. Agus MS, Steil GM, Wypij D, et al. Tight glycemic control vs standard care after pediatric cardiac surgery. N Engl J Med. 2012;367:1208-19.
22. Harris DL, Battin MR, Weston PJ, Harding J. Continuous glucose monitoring in newborn babies at risk of hypoglycemia. J Pediatr. 2010;157:198-202. e1.
23. Hay Jr WW, Rozance PJ. Continuous glucose monitoring for diagnosis and treatment of neonatal hypoglycemia. J Pediatr. 2010;157:180-2.
24. Schiaffini R, Brufani C, Russo B, et al. Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system. Eur J Endocrinol. 2010;162:705-10.
25. Hershkovitz E, Rachmel A, Ben-Zaken H, Phillip M. Continuous glucose monitoring in children with glycogen storage disease type I. J Inherit Metab Dis. 2001;24:863-9.
26. White FJ, Jones SA. The use of continuous glucose monitoring in the practical management of glycogen storage disorders. J Inherit Metab Dis. 2011;34:631-42.
27. Steil GM, Rebrin K, Mastrototaro J, et al. Determination of plasma glucose during rapid glucose excursions with a subcutaneous glucose sensor. Diabetes Technol Ther. 2003;5:27-31.
28. Cengiz E, Sherr JL, Weinzimer SA, Tamborlane WV. New-generation diabetes management: glucose sensor-augmented insulin pump therapy. Expert Rev Med Devices. 2011;8:449-58.
29. Rebrin K, Sheppard Jr NF, Steil GM. Use of subcutaneous interstitial fluid glucose to estimate blood glucose: revisiting delay and sensor offset. J Diabetes Sci Technol. 2010;4:1087-98.
30. Voskanyan G, Keenan B, Mastrototaro J, Steil G. Putative delays in interstitial fluid (ISF) glucose kinetics can be attributed to the glucose sensing systems used to measure them rather than the delay in ISF glucose itself. J Diabetes Sci Technol. 2007;1:639-44.
31. Keenan DB, Mastrototaro JJ, Zisser H, et al. Accuracy of the Enlite 6-day glucose sensor with guardian and Veo calibration algorithms. Diabetes Technol Ther. 2012;14:225-31.
32. Christiansen M, Bailey T, Watkins E. A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technol. Ther. 2013;15:1-8.
33. Gifford R, Batchelor MM, Lee Y, et al. Mediation of in vivo glucose sensor inflammatory response via nitric oxide release. J Biomed Mater Res A. 2005;75:755-66.
34. Klueh U, Kaur M, Qiao Y, Kreutzer D. Critical role of tissue mast cells in controlling long-term glucose sensor function in vivo. Biomaterials. 2010;31:4540-51.
35. Klueh U, Liu Z, Feldman B, et al. Metabolic biofouling of glucose sensors in vivo: role of tissue microhemorrhages. J Diabetes Sci Technol. 2011;5:583-95.
36. Klueh U, Liu Z, Feldman B, Kreutzer D. Importance of interleukin-1 and interleukin-1 receptor antagonist in short-term glucose sensor function in vivo. J Diabetes Sci Technol. 2010;4:1073-86.
37. Helton KL, Ratner BD, Wisniewski NA. Biomechanics of the sensor-tissue interface-effects of motion, pressure, and design on sensor performance and foreign body response-part II: examples and application. J Diabetes Sci Technol. 2011;5:647-56.
38. Gilligan BJ, Shults MC, Rhodes RK, Updike SJ. Evaluation of a subcutaneous glucose sensor out to 3 months in a dog model. Diabetes Care. 1994;17:882-7.
39. Buckingham BA, Kollman C, Beck R, et al. Evaluation of factors affecting CGMS calibration. Diabetes Technol Ther. 2006;8:318-25.
40. Kamath A, Mahalingam A, Brauker J. Analysis of time lags and other sources of error of the DexCom SEVEN continuous glucose monitor. Diabetes Technol Ther. 2009;11:689-95.
41. Mazze RS, Strock P, Borgman S, et al. Evaluating the accuracy, reliability, and clinical applicability of continuous glucose monitoring (CGM): is CGM ready for real-time? Diabetes Technol Ther. 2009;11:11-8.
42. Kordonouri O, Pankowska E, Kami B, et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia. 2010;53:2487-95.
43. Ramchandani N, Arya S, Ten S, Bhandari S, et al. Real-life utilization of real-time continuous glucose monitoring: the complete picture. J Diabetes Sci Technol. 2011;5:860-70.
44. Vaddiraju S, Burgess DJ, Tomazos I, et al. Technologies for continuous glucose monitoring: current problems and future promises. J Diabetes Sci Technol. 2010;4:1540-62.
45. Gough DA, Kurnosa LS, Routh TL, et al. Function of an implanted tissue glucose sensor for more than 1 year in animals. Sci Transl Med. 2010;2:42-53.
46. Cobelli C, Renard E, Kovatchev BP, et al. Pilot studies of wearable outpatient artificial pancreas in type 1 diabetes. Diabetes Care. 2012;35:e65-7.
47. Wilinska ME, Budiman HS, Taub MB, et al. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci Technol. 2009;3:1109-20.
48. Castle JR, Pitts A, Hanavan K, et al. The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes. Diabetes Care. 2012;35:706-10.